Table 2.

Summary of results.

Study Details	Study Design	Population	Intervention	Comparator(s)	Outcome measure
Shaker, 2022; 9	Economic analysis	600,000 simulated patients at low, moderate, and high-riskfor SCA	SMall AED for Rapid Treatment of SCA (SMART) strategy	No SMART strategy	At a 1.6% SCA annual risk, SMART strategy was associated with $95,251/QALY (societal perspective) and $100,797/QALY (healthcare perspective). At a 3.5% SCA annual risk, SMART strategy was associated with $53,925/QALY (societal perspective) and and $59,672/QALY (healthcare perspective). SMART prevented 1,762 fatalities across risk strata (1.59% fatality relative risk reduction across groups).
Todd, 2023; 16	Cluster-randomised controlled trial − Study protocol	Sample size calculation of 714 (357 per arm)	Community responder dispatched with GoodSAM app equipped with an ultraportable AED	Community responder not equipped with AED	Primary outcome will be survival to 30 days.Aim to detect a 7% increase in survival (9% to 16%)
Todd, 2023; 19	Cluster randomized intervention −preliminary trial results (abstract)	1805 community responders recruited, 903 allocated to CellAED	Community responder dispatched with GoodSAM app equipped with an ultraportable defibrillator (CellAED) n = 903	Community responder not equipped with AED	Unfinished study. 1,788 alerts to CellAED participants, 104 arriving before EMS.

AED: Automated External Defibrillator, QALY: Quality Adjusted Life Year, SCA: Sudden Cardiac Death.